Introduction. Treatment of lower urinary tract infection primarily involves the antibiotics. However, the efficiency of antibacterial therapy has significantly decreased. Immunomodulators are recognized as the most important link in the pathogenetic therapy of chronic cystitis, which can prevent the development of chronic inflammation. In recent years, a number of publications have appeared proving the benefits of immunomodulatory therapy.
Aim. To carry out a comparative analysis of the efficiency of various dosages of the drug VIFERON® for the combination treatment of chronic recurrent bacterial cystitis.
Materials and methods. A total of 90 women aged from 18 to 45 years with chronic bacterial cystitis in the acute stage were included in the study. They were divided into 3 groups of 30 each. In group 1, women received antibacterial therapy. In group 2, the drug VIFERON® was prescribed in the form of suppositories of 1,000,000 IU rectally for 10 days in combination with antibacterial therapy. In group 3, standard antibacterial therapy was prescribed with VIFERON® b at 3,000,000 IU rectally for 10 days. The follow-up was carried out on the 1st, 5th and 10th days.
Results. On the 1st day in both groups there were signs of exacerbation of chronic cystitis, such as frequent urination, burning during urination, urgency, nocturia, leukocyturia. The results of clinical and laboratory studies obtained on the 5th day of therapy in groups 2 and 3 differed significantly (p<0.05) from those in group 1. In addition, the number of episodes of nocturia and urgency per day, and the pain intensity were closer to normal in group 3. These differences were also significant (p<0.05). By the 10th day of therapy, the average values of the clinical and laboratory parameters decreased to normal levels in all three groups; there were no significant differences (p<0.05). Despite the fact that at baseline bacterial nature of the cystitis was confirmed in all patients, by the 5th day of therapy, eradication of the pathogen was registered in all cases.
Conclusion. A combination of immunomodulators and antibiotics results in a rapid significant improvement in women with chronic bacterial cystitis by the 5th day of therapy. The use of the drug VIFERON® at a dose of 3,000,000 IU in combination with antibacterial therapy demonstrated the greatest efficiency in clinical and laboratory manifestations.

Keywords: VIFERON®, lower urinary tract infections, immunotherapy, chronic cystitis, interferon alpha